The AL001 program is the primary focus of Alzamend Neuro's research and development efforts. AL001 is an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate. Research and development activities include preclinical studies, Phase II clinical trials, and formulation development. The technology aims to treat Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The patient impact is significant, as AL001 has the potential to slow or halt the progression of these debilitating conditions. Market positioning is based on the unmet need for effective treatments in these areas. Future opportunities include expanding the indications for AL001 and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships with research institutions like Massachusetts General Hospital and QMENTA are crucial for advancing the program.

AL002 represents Alzamend Neuro's cell-based therapeutic vaccine approach. This segment focuses on developing a method using a mutant-peptide sensitized cell to restore the ability of a patient's immunological system to combat Alzheimer's. Research and development activities include cell culture, immunological assays, and preclinical studies to assess safety and efficacy. The technology leverages the patient's own immune system to target and eliminate amyloid plaques, a hallmark of Alzheimer's disease. The therapeutic area is Alzheimer's disease, with the potential to significantly improve patient outcomes by slowing disease progression and improving cognitive function. Market positioning is based on the innovative approach to immunotherapy for Alzheimer's. Future opportunities include expanding the scope of the vaccine to other neurodegenerative diseases. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy.